Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Eytan M SteinDaniel J DeAngeloJörg ChromikManik ChatterjeeSebastian BauerChia-Chi LinCristina SuarezFilip Yves Francine De VosNeeltje SteeghsPhilippe Alexandre CassierDavid TaiJean-Jacques KiladjianNoboru YamamotoRogier MousJordi EsteveHironobu MinamiStéphane FerrettiNelson GuerreiroChristophe MeilleRajkumar RadhakrishnanBernard PereiraLuisa MaricontiEnsar HalilovicClaire FabreCecilia CarpioPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
A common safety profile was identified and preliminary activity was noted, particularly in AML. Comprehensive investigation of dosing regimens yielded recommended doses/regimens for future combination studies.